Richard Geary - Ionis Pharmaceuticals Executive Officer
| IONS Stock | USD 35.90 0.53 1.50% |
Executive
Dr. Richard S. Geary, Ph.D., is Senior Vice President Development of Ionis Pharmaceuticals Inc. From August 2003 to August 2008, Dr. Geary served as our Vice President, Preclinical Development. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Prior to joining Ionis in 1995, Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute. since 2008.
| Age | 66 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Address | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 |
| Phone | 760 931 9200 |
| Web | https://www.ionispharma.com |
Ionis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0725) % which means that it has lost $0.0725 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7338) %, meaning that it created substantial loss on money invested by shareholders. Ionis Pharmaceuticals' management efficiency ratios could be used to measure how well Ionis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.13 in 2024. Return On Capital Employed is likely to drop to -0.15 in 2024. At this time, Ionis Pharmaceuticals' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 365.6 M in 2024, whereas Intangible Assets are likely to drop slightly above 24.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dana Aftab | Exelixis | 60 | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Jennifer McDonough | Krystal Biotech | N/A | |
| Gary Grote | Halozyme Therapeutics | N/A | |
| Alison Nasisi | Sarepta Therapeutics | N/A | |
| Sheila Denton | Incyte | 58 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Yen Wing | Biomarin Pharmaceutical | N/A | |
| Kevin Eggan | Biomarin Pharmaceutical | N/A | |
| Tony Redmond | Exelixis | N/A | |
| Paula Swain | Incyte | 66 | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| Brian MD | Iovance Biotherapeutics | N/A | |
| Mark Delong | Apellis Pharmaceuticals | 47 | |
| David JD | Akero Therapeutics | N/A | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Hubert MD | Krystal Biotech | 55 | |
| Scott Gangloff | Akero Therapeutics | 50 | |
| Mark Esq | Halozyme Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.0725 |
Ionis Pharmaceuticals Leadership Team
Elected by the shareholders, the Ionis Pharmaceuticals' board of directors comprises two types of representatives: Ionis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ionis. The board's role is to monitor Ionis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ionis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ionis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Esq, Chief VP | ||
| Eric Swayze, Executive Research | ||
| Wade Walke, Vice President - Corporate Communications | ||
| Brett Monia, Sr. VP of Drug Discovery and Corporate Devel. | ||
| Frank Bennett, Senior Vice President - Antisense Research | ||
| MA MBA, Executive CFO | ||
| Hayley Soffer, Vice Communications | ||
| JD Esq, Strategic Director | ||
| Joel Edwards, VP Operations | ||
| Stanley Crooke, Chairman of the Board and Presidentident, CEO | ||
| Elizabeth Hougen, CFO and Sr. VP of Fin. | ||
| Richard Geary, Executive Officer | ||
| Onaiza CadoretManier, Chief VP | ||
| Darren Gonzales, Chief VP | ||
| Dr BSc, Executive Officer |
Ionis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ionis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.73 | ||||
| Return On Asset | -0.0725 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (1.11) % | ||||
| Current Valuation | 4.63 B | ||||
| Shares Outstanding | 157.9 M | ||||
| Shares Owned By Insiders | 0.76 % | ||||
| Shares Owned By Institutions | 99.24 % | ||||
| Number Of Shares Shorted | 11.05 M | ||||
| Price To Earning | 101.16 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.